RecruitingPhase 1NCT06297525

Study of STP938 in Advanced Solid Tumours

An Open-Label, Phase 1 Study to Evaluate Safety, Tolerability and Pharmacokinetics of the CTPS1 Inhibitor STP938 in Adult Subjects With Advanced Solid Tumors, With a Safety Expansion in Advanced CTPS2 Null Ovarian Cancer

Sponsor

Step Pharma, SAS

Enrollment

70 participants

Start Date

Aug 2, 2024

Study Type

INTERVENTIONAL

Conditions

Solid Tumor

Summary

The Phase 1a part of the study is a dose escalation of STP938 as a monotherapy. The Phase 1b part of the study is a safety expansion cohort of STP938 as a monotherapy.

Eligibility

Min Age: 18 Years

Plain Language Summary

Simplified for easier understanding

This is an early-phase (first-in-human) study testing STP938, a new experimental drug, in patients with advanced solid tumors that are no longer responding to available treatments. **You may be eligible if...** - You are 18 or older with a confirmed advanced solid tumor that cannot be cured by existing therapies - You have measurable disease on scans - Your general health and organ function are adequate - You have tumor tissue available for biomarker testing - Prior treatment side effects have resolved to mild or baseline levels **You may NOT be eligible if...** - You are pregnant or breastfeeding - You have active cancer spread to the brain or spinal fluid - You have had another active cancer within the past 2 years - You received radiation or other cancer treatment too recently - You have uncontrolled other serious illnesses - You are not willing to comply with contraception requirements Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.